Telomir Pharmaceuticals (TELO) Profit After Tax (2023 - 2026)

Telomir Pharmaceuticals has reported Profit After Tax for 3 years, with the latest figure at -$2.1 million in Q4 2025.

• Quarterly Profit After Tax rose 28.88% year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.4 million (up 37.01% YoY) and the FY2025 annual result came in at -$10.4 million, up 37.01% from the prior year.
• Profit After Tax retreated to -$2.1 million in Q4 2025 per TELO's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$482938.0 in Q1 2023 and troughed at -$9.3 million in Q4 2023.
• A 3-year average of -$3.3 million and a median of -$2.1 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 1195.12% in 2024, then surged 81.6% in 2025.
• Over 3 years, Profit After Tax stood at -$9.3 million in 2023, then jumped by 68.93% to -$2.9 million in 2024, then increased by 28.88% to -$2.1 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.1 million, -$1.1 million, and -$5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.